Medivation Inc (MDVN.OQ)
|Market Cap (Mil.):||$4,725.02|
|Shares Outstanding (Mil.):||75.46|
* Patients showed rise in overall survival and survival without cancer worsening
Oct 22 - Medivation Inc and its Japanese partner Astellas Pharma Inc said a late-stage trial of their experimental prostate cancer drug met the main goal of improving patients' survival.
LONDON - Britain's healthcare cost watchdog NICE has recommended that a new prostate cancer pill from Medivation and Astellas should be used on the state health service.
LONDON, Oct 18 - Britain's healthcare cost watchdog NICE has recommended that a new prostate cancer pill from Medivation and Astellas should be used on the state health service.
|Johnson & Johnson (JNJ.N)||$93.63||-0.34|
|Sanofi SA (SASY.PA)||€74.92||+0.11|
|Bayer AG (BAYGn.DE)||€95.75||-1.41|
|Bayer AG (BAYE.F)||--||--|
|Novartis AG (NOVN.VX)||CHF70.65||-0.50|
|Merck & Co., Inc. (MRK.N)||$49.31||-0.45|
|Roche Holding Ltd. (ROG.VX)||CHF244.60||-4.10|
|Abbott Laboratories (ABT.N)||$37.36||-0.24|
|Eli Lilly & Co. (LLY.N)||$49.86||+0.08|
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Provider: S&P Capital IQ Quantitative Report
Provider: Pechala's Reports
Provider: Ford Investor Services, Inc.
Provider: ValuEngine, Inc.
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.